FDA, DEA Pushed to Make Gabapentin a Controlled Substance

In a bid to stop abuse and diversion of the anticonvulsant gabapentin, a watchdog group is petitioning federal regulators to make the drug a controlled substance. The nonprofit group Public Citizen has filed a petition with the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), arguing that medication’s risks additional safeguards. … Read more

Placebo Response in Neuropathic Pain Trials

The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Both placebo and nocebo effects can greatly affect the interpretation of outcomes in randomized controlled trials of chronic neuropathic pain treatments. When trials are being designed and interpreted, these effects need to be … Read more